FDA delays decision on BeiGene's cancer drug on COVID restrictions

China-based drug developer BeiGene said on Thursday the U.S. Food and Drug Administration (FDA) has delayed its decision on the company's cancer drug as it was unable to conduct inspections in the country due to COVID-related travel curbs.